WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406623
CAS#: 765958-29-0
Description: SMK-17 is a potent MEK1/2 inhibitor with high aqueous solubility. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects.
Hodoodo Cat#: H406623
Name: SMK-17
CAS#: 765958-29-0
Chemical Formula: C20H24ClF2IN4O2S
Exact Mass: 584.03
Molecular Weight: 584.850
Elemental Analysis: C, 41.07; H, 4.14; Cl, 6.06; F, 6.50; I, 21.70; N, 9.58; O, 5.47; S, 5.48
Synonym: SMK17; SMK 17; SMK17.
IUPAC/Chemical Name: N-(2-((2-chloro-4-iodophenyl)amino)-3,4-difluorophenyl)-4-(isopropylamino)piperidine-1-sulfonamide
InChi Key: WEULUYVOTSCFRJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H24ClF2IN4O2S/c1-12(2)25-14-7-9-28(10-8-14)31(29,30)27-18-6-4-16(22)19(23)20(18)26-17-5-3-13(24)11-15(17)21/h3-6,11-12,14,25-27H,7-10H2,1-2H3
SMILES Code: O=S(N1CCC(NC(C)C)CC1)(NC2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3Cl)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 584.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Kiga, M. Method for predicting responsiveness to MAPK signaling pathway-inhibiting compound by detecting mutation of β-catenin, reagent for detecting the mutation, and treatment of cancer with MAPK signaling pathway inhibitor. WO2014133071A1.